Blood pressure (BP) management involves the use of magnesium (Mg). Irregularities in serum magnesium are prevalent in chronic kidney disease (CKD), nonetheless its relationship with the advancement of hypertension and CKD development in patients with CKD is blurry. We dissected information from 3866 partakers from the CRIC Study (Chronic Renal Insufficiency Cohort). The relationship between serum magnesium with standard systolic BP (SBP) and diastolic BP (DBP) was surveyed using linear regression. Logistic regression investigated the relationship of serum magnesium with different meanings of hypertension. Cox proportional-hazards models investigated the danger of episodic hypertension and CKD advancement. Results showed the value of mean serum magnesium was 2.0 mEq/L (±0.3 mEq/L). Decreased systolic BP (−3.4 mm Hg) and lesser diastolic BP (−2.9 mm Hg) were interrelated with increased Mg. Increased Mg was related with a lower hazard of American Heart Association–characterized hypertension (SBP≥130 mm Hg or DBP≥80 mm Hg) at pattern (changed peril proportion, 0.65 [95% CI, 0.49–0.86 per 1 mEq/L]), a lower hazard of not well controlled BP (SBP≥120 mm Hg or DBP≥80 mm Hg; changed chances proportion, 0.58 [95% CI, 0.43–0.78 per 1 mEq/L]). On time-to-event investigations, greater baseline serum Mg was related with an ostensibly lower hazard of occurrence CRIC-characterized hypertension (changed danger proportion, 0.77 [95% CI, 0.46–1.31 per 1 mEq/L]). Higher magnesium was related with an essentially lower hazard of CKD movement (changed peril proportion, 0.68 [95% CI, 0.54–0.86 per 1 mEq/L]). In patients with CKD, higher serum magnesium is related with lower SBP and DBP, and with a lower hazard of hypertension and CKD movement. In patients with CKD, regardless of whether magnesium supplementation could streamline BP control and forestall infection movement merits further examination.